| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2013: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2012: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2011: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
|---|
| Research Abstract |
We showed regulatory T cells that suppress important immune responses are expanded or induced by antigen presenting dendritic cells. Regulatory T cell is a promising therapy for autoimmunity, graft rejection and allergy. To develop an effective regulatory-T cell therapy, we studied followings. 1) What kinds of innate signals keep regulatory T cell survive long in vivo? 2) To suppress only unwanted responses, are there any innate signals that expand regulatory T cells specifically? We have found that TLR 2 signals that activate dendritic cells maintain regulatory T cell survival and function in vivo. We also found that dendritic cells from oral cavity induce regulatory T cells specifically. And, we are currently investigating a dendritic-cell activating signal that expands regulatory T cell up to about 60% of CD4+T cells in the skin.
|
